Ticker | Name | Price | Change | Change % | Volume | Trades |
---|---|---|---|---|---|---|
REMO | RemSense Technologies Ltd | 0.002 | 0.001 | 100.00% | 500,000 | 4 |
BGT | BioGene Technology Ltd | 0.054 | 0.022 | 68.75% | 23,601,476 | 688 |
ENVO | Enova Mining Ltd | 0.003 | 0.001 | 50.00% | 170,000 | 1 |
AOK | Australian Oil Company Ltd | 0.003 | 0.001 | 50.00% | 25,000 | 1 |
NRZ | NeuRizer Ltd | 0.003 | 0.001 | 50.00% | 11,989,145 | 21 |
NAE | New Age Exploration Limited | 0.004 | 0.001 | 33.33% | 1,029,124 | 3 |
REM | RemSense Technologies Ltd | 0.046 | 0.011 | 31.43% | 2,309,264 | 84 |
RAN | Range International Limited | 0.005 | 0.001 | 25.00% | 647,684 | 11 |
DMG | Dragon Mountain Gold | 0.005 | 0.001 | 25.00% | 15,000 | 1 |
NCCO | NAOS Emerging Opportunities Company Limited | 0.005 | 0.001 | 25.00% | 12,639 | 1 |
ENV | Enova Mining Ltd | 0.005 | 0.001 | 25.00% | 8,716,011 | 29 |
35% objective response rate (ORR) in second-line colorectal cancer (CRC) patients treated with sirexatamab (DKN-01) plus bevacizumab and chemotherapy, compared to 23% ORR in the control arm DKK1 levels highly correlated with clinical activity in CRC population ORR benefit with sirexatamab observed across multiple potential Phase 3 CRC populations Preparations will begin for a registrational Phase 3 study in second-line CRC patients DisTinGuish Part C study in gastric cancer demonstrates activity in biomarker populations, but not the signal necessary to advance into Phase 3 Leap to host a conference call to present clinical data today, January 28, 2025, at 8:00 a.m. ...
XIAMEN, China, Jan. 28, 2025 /PRNewswire/ -- Lichen China Limited (Nasdaq: LICN) ("Lichen China" or the "Company"), a dedicated financial and taxation service provider in China today announced that it has entered into a definitive agreement with several investors for the purchase and sale of an aggregate of 42,500,000 of the Company's Class A ordinary share, par value $0.00004 per share (the "Shares") (or pre-funded warrants in lieu thereof) at a purchase price of $0.08 per share in a registered direct offering. The purchase price for the pre-funded warrants is identical to the purchase price for Shares, less the exercise price of ...
JetBlue (NASDAQ: JBLU) today announced it will be ‘kicking off’ limited time nonstop flights to bring hundreds more sports fans to the big game. The airline will add flights in Newark and from its home at New York’s JFK Airport to New Orleans, giving football fans in JetBlue cities the perfect play and more options to cheer on their team and get in on the action. Flights are now available for booking on jetblue.com.
This financing is expected to support filing of New Drug Applications for NRX-100 (ketamine) and NRX-101, and to support launch of HOPE TherapeuticsInvestment consists of $3.5 million in above the market equity and $5.4 million in Senior Secured Notes; expected to fund current operations into 2026WILMINGTON, Del., Jan. 28, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) ("NRx", "NRx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical company, today announced that it has entered into a binding agreement for a registered direct offering of its common stock with expected gross proceeds of $3.5 million (the "Financing") with certain institutional investors. The Company ...
Ticker | Name | Price | Change | Change % | Market Cap | Volume |
---|---|---|---|---|---|---|
BTC | Bitcoin | 102,529.72 | 1,196.46 | 1.18% | 2.03T | 5,478,409,039 |
ETH | Ethereum | 3,149.94 | 73.28 | 2.38% | 378.61B | 2,856,518,629 |
XRP | Ripple | 3.11 | 0.050 | 1.63% | 175.35B | 2,043,312,048 |
USDT | Tether USD | 0.99959 | 0.00018 | 0.02% | 119.62B | 504,550,586 |
SOL | Solana | 233.67 | 6.66 | 2.93% | 109.62B | 1,540,848,090 |
BNB | Binance Coin | 673.72 | 12.53 | 1.89% | 106.41B | 180,911,817 |
DOGE | Dogecoin | 0.33145 | 0.0126 | 3.95% | 48.49B | 600,259,619 |
USDC | USD Coin | 1.00 | 0.0001 | 0.01% | 35.56B | 961,695,154 |
ADA | Cardano | 0.9415 | 0.0259 | 2.83% | 33.62B | 241,942,197 |
STETH | stETH | 3,152.31 | 78.11 | 2.54% | 30.78B | 3,785,037 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions